The article discusses that the single-agent mosunetuzumab is a safe and clinically promising chemotherapy-free therapy for elderly and unfit patients with untreated diffuse large B-cell lymphoma (DLBCL). It mentions that the Mosunetuzumab is a fully humanized immunoglobulin G1 anti-CD20 and anti-CD3 bispecific antibody that redirects T-cells to engage and eliminate malignant B-cells.